Clinical Trials Market Size & Share | Forecast Report 2026-2035

Clinical Trials Market – By Phase, By Study Design, Therapeutic Area, By Service Type, Global Forecast (2026 - 2035)

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology and Scope

1.1&nbsp;&nbsp;&nbsp; Market scope and definition

1.2&nbsp;&nbsp;&nbsp; Research approach

1.3&nbsp;&nbsp;&nbsp; Quality commitments

1.3.1&nbsp;&nbsp;&nbsp; GMI AI policy and data integrity commitment

1.3.1.1&nbsp;&nbsp;&nbsp; Source consistency protocol

1.4&nbsp;&nbsp;&nbsp; Research trail and confidence scoring

1.4.1&nbsp;&nbsp;&nbsp; Research trail components

1.4.2&nbsp;&nbsp;&nbsp; Scoring components

1.5&nbsp;&nbsp;&nbsp; Data collection

1.5.1&nbsp;&nbsp;&nbsp; Partial list of primary sources

1.6&nbsp;&nbsp;&nbsp; Data mining sources

1.6.1&nbsp;&nbsp;&nbsp; Paid sources

1.6.1.1&nbsp;&nbsp;&nbsp; Sources, by region

1.7&nbsp;&nbsp;&nbsp; Base estimates and calculations

1.7.1&nbsp;&nbsp;&nbsp; Revenue share analysis

1.7.2&nbsp;&nbsp;&nbsp; Base year calculation

1.8&nbsp;&nbsp;&nbsp; Forecast model

1.9&nbsp;&nbsp;&nbsp; Research transparency addendum

1.9.1&nbsp;&nbsp;&nbsp; Source attribution framework

1.9.2&nbsp;&nbsp;&nbsp; Quality assurance metrics

1.9.3&nbsp;&nbsp;&nbsp; Our commitment to trust

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Industry 360&#176; synopsis

2.2&nbsp;&nbsp;&nbsp; Key market trends

2.2.1&nbsp;&nbsp;&nbsp; Regional trends

2.2.2&nbsp;&nbsp;&nbsp; Phase trends

2.2.3&nbsp;&nbsp;&nbsp; Study design trends

2.2.4&nbsp;&nbsp;&nbsp; Therapeutic area trends

2.2.5&nbsp;&nbsp;&nbsp; Service type trends

2.3&nbsp;&nbsp;&nbsp; CXO perspectives: Strategic imperatives

Chapter 3&nbsp;&nbsp;&nbsp;Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp; Increasing prevalence of chronic diseases across the globe

3.2.1.2&nbsp;&nbsp;&nbsp; Growing demand for outsourcing clinical trials to CROs

3.2.1.3&nbsp;&nbsp;&nbsp; Rise in government and non-government funding for clinical trials

3.2.1.4&nbsp;&nbsp;&nbsp; Growing opportunities for conducting clinical trials in countries in Asia Pacific

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls and challenges

3.2.2.1&nbsp;&nbsp;&nbsp; Lack of standard-of-care coverage from insurance providers

3.2.2.2&nbsp;&nbsp;&nbsp; Infrastructural barriers and social hurdles

3.2.3&nbsp;&nbsp;&nbsp; Market opportunities

3.2.3.1&nbsp;&nbsp;&nbsp; Growth of decentralized clinical trials (DCTs)

3.2.3.2&nbsp;&nbsp;&nbsp; Integration of artificial intelligence and advanced analytics

3.3&nbsp;&nbsp;&nbsp; Clinical trials volume analysis (Driven by Primary Research)

3.3.1&nbsp;&nbsp;&nbsp; Clinical trials volume analysis, by region, 2022 - 2025

3.3.2&nbsp;&nbsp;&nbsp; Clinical trials volume analysis, by phase of development, 2022 - 2025

3.3.3&nbsp;&nbsp;&nbsp; Clinical trials volume analysis, by indication, 2022 - 2025

3.4&nbsp;&nbsp;&nbsp; Regulatory landscape (Driven by Primary Research)

3.4.1&nbsp;&nbsp;&nbsp; U.S.

3.4.2&nbsp;&nbsp;&nbsp; Europe

3.4.3&nbsp;&nbsp;&nbsp; Asia Pacific

3.4.3.1&nbsp;&nbsp;&nbsp; Singapore

3.4.3.2&nbsp;&nbsp;&nbsp; Malaysia

3.4.3.3&nbsp;&nbsp;&nbsp; Indonesia

3.4.3.4&nbsp;&nbsp;&nbsp; Thailand

3.4.3.5&nbsp;&nbsp;&nbsp; South Korea

3.4.3.6&nbsp;&nbsp;&nbsp; Philippines

3.5&nbsp;&nbsp;&nbsp; Clinical trials - Asia Pacific advantage (Driven by Primary Research)

3.6&nbsp;&nbsp;&nbsp; Impact of AI and Gen AI on the market

3.7&nbsp;&nbsp;&nbsp; Porters analysis

3.8&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2025

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company market share analysis

4.3&nbsp;&nbsp;&nbsp; Company matrix analysis

4.4&nbsp;&nbsp;&nbsp; Competitive analysis of major market players

4.5&nbsp;&nbsp;&nbsp; Competitive positioning matrix

4.6&nbsp;&nbsp;&nbsp; Key developments

4.6.1&nbsp;&nbsp;&nbsp; Merger and acquisition

4.6.2&nbsp;&nbsp;&nbsp; Partnership and collaboration

4.6.3&nbsp;&nbsp;&nbsp; New product launches

4.6.4&nbsp;&nbsp;&nbsp; Expansion plans

Chapter 5&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Phase, 2022 - 2035 ($ Mn)

5.1&nbsp;&nbsp;&nbsp; Key trends

5.2&nbsp;&nbsp;&nbsp; Phase I

5.3&nbsp;&nbsp;&nbsp; Phase II

5.4&nbsp;&nbsp;&nbsp; Phase III

5.5&nbsp;&nbsp;&nbsp; Phase IV

Chapter 6&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Study Design, 2022 - 2035 ($ Mn)

6.1&nbsp;&nbsp;&nbsp; Key trends

6.2&nbsp;&nbsp;&nbsp; Interventional study

6.3&nbsp;&nbsp;&nbsp; Observational study

6.4&nbsp;&nbsp;&nbsp; Expanded access study

Chapter 7&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Therapeutic Area, 2022 - 2035 ($ Mn)

7.1&nbsp;&nbsp;&nbsp; Key trends

7.2&nbsp;&nbsp;&nbsp; Autoimmune disease

7.3&nbsp;&nbsp;&nbsp; Oncology

7.4&nbsp;&nbsp;&nbsp; Cardiology

7.5&nbsp;&nbsp;&nbsp; Infectious disease

7.6&nbsp;&nbsp;&nbsp; Dermatology

7.7&nbsp;&nbsp;&nbsp; Ophthalmology

7.8&nbsp;&nbsp;&nbsp; Neurology

7.9&nbsp;&nbsp;&nbsp; Hematology

7.10&nbsp;&nbsp;&nbsp; Other therapeutic areas

Chapter 8&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Service Type, 2022 - 2035 ($ Mn)

8.1&nbsp;&nbsp;&nbsp; Key trends

8.2&nbsp;&nbsp;&nbsp; Outsourcing service

8.3&nbsp;&nbsp;&nbsp; In-house service

Chapter 9&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

9.1&nbsp;&nbsp;&nbsp; Key trends

9.2&nbsp;&nbsp;&nbsp; North America

9.2.1&nbsp;&nbsp;&nbsp; U.S.

9.2.2&nbsp;&nbsp;&nbsp; Canada

9.3&nbsp;&nbsp;&nbsp; Europe

9.3.1&nbsp;&nbsp;&nbsp; Germany

9.3.2&nbsp;&nbsp;&nbsp; UK

9.3.3&nbsp;&nbsp;&nbsp; France

9.3.4&nbsp;&nbsp;&nbsp; Spain

9.3.5&nbsp;&nbsp;&nbsp; Italy

9.3.6&nbsp;&nbsp;&nbsp; Poland

9.3.7&nbsp;&nbsp;&nbsp; Netherlands

9.3.8&nbsp;&nbsp;&nbsp; Switzerland

9.3.9&nbsp;&nbsp;&nbsp; Russia

9.4&nbsp;&nbsp;&nbsp; Asia Pacific

9.4.1&nbsp;&nbsp;&nbsp; China

9.4.2&nbsp;&nbsp;&nbsp; Japan

9.4.3&nbsp;&nbsp;&nbsp; India

9.4.4&nbsp;&nbsp;&nbsp; Australia

9.4.5&nbsp;&nbsp;&nbsp; South Korea

9.4.6&nbsp;&nbsp;&nbsp; Singapore

9.4.7&nbsp;&nbsp;&nbsp; Malaysia

9.4.8&nbsp;&nbsp;&nbsp; Indonesia

9.4.9&nbsp;&nbsp;&nbsp; Thailand

9.4.10&nbsp;&nbsp;&nbsp; Philippines

9.5&nbsp;&nbsp;&nbsp; Latin America

9.5.1&nbsp;&nbsp;&nbsp; Brazil

9.5.2&nbsp;&nbsp;&nbsp; Mexico

9.5.3&nbsp;&nbsp;&nbsp; Argentina

9.5.4&nbsp;&nbsp;&nbsp; Colombia

9.5.5&nbsp;&nbsp;&nbsp; Peru

9.6&nbsp;&nbsp;&nbsp; Middle East and Africa

9.6.1&nbsp;&nbsp;&nbsp; Saudi Arabia

9.6.2&nbsp;&nbsp;&nbsp; South Africa

9.6.3&nbsp;&nbsp;&nbsp; UAE

Chapter 10&nbsp;&nbsp;&nbsp;Company Profiles

10.1&nbsp;&nbsp;&nbsp; Cadiya (Clinipace)

10.2&nbsp;&nbsp;&nbsp; Celerio

10.3&nbsp;&nbsp;&nbsp; Charles River Laboratories

10.4&nbsp;&nbsp;&nbsp; ClinChoice

10.5&nbsp;&nbsp;&nbsp; ICON plc

10.6&nbsp;&nbsp;&nbsp; IQVIA HOLDINGS

10.7&nbsp;&nbsp;&nbsp; Labcorp Holding (Covance )

10.8&nbsp;&nbsp;&nbsp; Medpace

10.9&nbsp;&nbsp;&nbsp; Parexel International Corporation

10.10&nbsp;&nbsp;&nbsp; Pharmaceutical Product Development (Thermo Fisher Scientific)

10.11&nbsp;&nbsp;&nbsp; Qserve

10.12&nbsp;&nbsp;&nbsp; SGS SA

10.13&nbsp;&nbsp;&nbsp; Syneos Health

10.14&nbsp;&nbsp;&nbsp; The Emmes Company

10.15&nbsp;&nbsp;&nbsp; Veeda

10.16&nbsp;&nbsp;&nbsp; Worldwide Clinical Trials

10.17&nbsp;&nbsp;&nbsp; Wuxi AppTec Co.

Clinical Trials Market

Customize This Report